« Return to News | Drug Sponsors

Presage and Millennium enter cancer research agreement

Monday, April 9, 2012 09:59 AM

Presage Biosciences, a Seattle, Wash.-based company that identifies clinically viable oncology drug combinations, has entered into a cancer research agreement with Millenium, Takeda’s oncology arm based in Cambridge, Mass.

Presage will receive upfront fees and research funding, as well as development and regulatory milestones related to identification of successful drug combinations. In return, Millennium with gain access to Presage’s proprietary technology platform to enable non-clinical identification of effective novel oncology drug combinations in solid tumors.

The patented Presage platform allows for the comparison of multiple drugs in the same tumor within a preclinical model. The technology has potential for application across the drug development process, from target identification to clinical trial patient selection.

“Presage’s technology platform allows us to obtain in-depth non-clinical in vivo data that is typically difficult to gather by conventional approaches,” said Joseph B. Bolen, Ph.D., chief scientific officer, Millennium. “It is our hope that the Presage platform will help us to more rapidly and accurately prioritize our development of novel combinations.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.